UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CARDIOVASCULAR & METABOLIC

Viatris

V

Viatris

Visit Website

About Viatris

Born from the 2020 combination of Mylan and Pfizer's Upjohn division, Viatris operates as one of the world's largest generic and established medicines companies, serving patients across more than 165 countries with a portfolio spanning both off-patent generics and branded products. The company's founding premise was to bridge the gap between innovation and access, ensuring that essential medicines reach patients regardless of geography or economic circumstance.

Portfolio Breadth and Therapeutic Reach

Viatris maintains a catalogue of approximately 1,400 molecules covering a wide range of therapeutic areas, including cardiovascular disease, infectious disease, central nervous system conditions, oncology, immunology, and respiratory health. The company is recognised as a leading global supplier of antiretrovirals for HIV treatment, a position inherited in part from Mylan's longstanding role in global health programmes. Its branded medicines include well-known products such as Lipitor (atorvastatin) and EpiPen, alongside an extensive generics and complex generics pipeline.

Global Manufacturing and Access Mission

Headquartered in Canonsburg, Pennsylvania, USA, and incorporated in 2020, Viatris operates a substantial global manufacturing network with facilities across North America, Europe, and Asia. The company is publicly listed on the Nasdaq exchange under the ticker symbol VTRS. Its scale enables a dual mandate: competing commercially in mature markets while actively supplying low- and middle-income countries through tiered pricing and partnership agreements with international health bodies.

Viatris has also pursued a strategic refocusing in recent years, divesting certain assets to concentrate resources on higher-value complex generics, biosimilars, and brand-name medicines. The biosimilars segment represents a growing area of investment, with the company working to commercialise alternatives to complex biologics across key markets. This evolution reflects a broader industry shift as the patent cliff for major biologics opens new competition opportunities for experienced generics manufacturers.

Further information is available at viatris.com.

Similar Companies

More in Cardiovascular & Metabolic

P

Pfizer

Pfizer is one of the world's largest research-based biopharmaceutical companies, with a history stretching back to 1849 and a presence in more than 125 countries. Headquartered in New York City, the company is listed on the New York Stock Exchange under the ticker PFE and is a constituent of the Dow Jones Industrial Average, reflecting its standing as a cornerstone of global healthcare. Core Therapy Areas and Pipeline Pfizer's portfolio spans oncology, internal medicine, vaccines, rare diseases, and hospital-acquired infections. The company's oncology business, built in part through the acquisition of Wyeth and later Medivation, includes targeted therapies that have become widely prescribed across breast, kidney, and lung cancers. Its vaccines division is among the largest globally, and the company's partnership with BioNTech to develop an mRNA-based vaccine during the COVID-19 pandemic brought its manufacturing and distribution capabilities to worldwide attention. The rare disease unit, operating under the Pfizer Rare Disease brand, addresses conditions with limited treatment options across haematology, neurology, and metabolic disorders. Global Scale and Manufacturing Pfizer operates one of the most extensive pharmaceutical manufacturing networks in the world, with dozens of production sites across North America, Europe, and Asia. Research and development investment consistently ranks among the highest in the industry, supporting a pipeline that at any given time includes hundreds of programmes at varying stages. The company's internal medicine portfolio includes long-established brands in cardiovascular disease, pain, and infectious disease alongside newer treatments for conditions such as atopic dermatitis. Pfizer has pursued a sustained acquisition strategy over decades, with landmark transactions including Warner-Lambert, Pharmacia, Wyeth, Hospira, and Array BioPharma, each expanding its therapeutic reach or manufacturing capacity. In 2022 the company acquired Global Blood Therapeutics and Arena Pharmaceuticals, and in 2023 completed the acquisition of Seagen, significantly strengthening its oncology pipeline with antibody-drug conjugate technologies. Further information is available at pfizer.com.

View profile
A

AstraZeneca UK

AstraZeneca is one of the world's largest biopharmaceutical companies, with its global headquarters at the Cambridge Biomedical Campus in England. Founded in 1999 through the merger of Astra AB of Sweden and Zeneca Group of the United Kingdom, the company is listed on the London Stock Exchange (AZN) and on Nasdaq, and employs approximately 90,000 people across more than 100 countries. Cambridge functions not merely as a corporate address but as the centre of the company's worldwide research and early development capability, hosting thousands of scientists working across discovery biology, chemistry, and translational medicine. Therapy Areas and Pipeline The company's research strategy concentrates on three main therapy area clusters: oncology, cardiovascular, renal and metabolic disease (CVRM), and respiratory and immunology (R&I). Within oncology, AstraZeneca markets established medicines including osimertinib (Tagrisso), olaparib (Lynparza, developed with MSD), and durvalumab (Imfinzi). The CVRM portfolio includes dapagliflozin (Farxiga/Forxiga), which has received regulatory approvals across heart failure, chronic kidney disease, and type 2 diabetes indications. The respiratory franchise covers budesonide/formoterol combinations and the biologic tezepelumab (Tezspire, developed with Amgen) for severe asthma. UK Operations and Clinical Development AstraZeneca UK operates across the full pharmaceutical value chain: early and late-stage clinical trials, regulatory affairs, medical affairs, market access, and commercial operations serving the National Health Service. The UK site at Cambridge is complemented by manufacturing and biologics development capabilities at sites including Macclesfield. The company collaborates extensively with the Medical Research Council, Cancer Research UK, and NHS England, and was a prominent partner in the University of Oxford COVID-19 vaccine programme, through which AstraZeneca's Vaxzevria was manufactured and distributed globally at no profit during the pandemic period. AstraZeneca participates in hundreds of sponsored clinical studies in the United Kingdom at any given time, engaging NHS trusts, academic medical centres, and independent research sites. The organisation also operates a patient access programme infrastructure and maintains a dedicated UK medical information service for healthcare professionals. Further information is available at astrazeneca.co.uk.

View profile
M

Medpace

Medpace is a scientifically driven contract research organisation (CRO) recognised for its full-service clinical development model and deep therapeutic expertise. Founded in 1992 and headquartered in Cincinnati, Ohio, the company has built its reputation on a differentiated approach: keeping scientific leadership in-house rather than outsourcing clinical operations, which allows for tighter integration across study design, regulatory strategy, and data management. The company serves a global client base spanning large pharmaceutical companies, biotechnology firms, and medical device manufacturers. Medpace operates across more than 40 countries and maintains a network of dedicated Phase I clinical pharmacology units alongside global laboratory services through its MedLabs subsidiary. This integrated laboratory capability, rare among CROs, supports bioanalytical testing, central laboratory functions, and specialised assay development without reliance on third parties. Medpace has developed particular depth in oncology, cardiology, and metabolic disease, areas where regulatory complexity and protocol sophistication demand experienced clinical teams. The company also carries notable strength in rare and orphan diseases, working with sponsors navigating accelerated pathways and adaptive trial designs. Its scientific advisory structure brings therapeutic area specialists directly into study oversight, a model the company has maintained as a core differentiator since its founding. Listed on the Nasdaq exchange under the ticker MEDP, Medpace has posted consistent growth and is widely regarded as one of the more profitable and operationally focused mid-to-large CROs in the sector. Its employee-ownership culture and low reliance on acquisitions distinguish it from larger conglomerate CROs that have grown primarily through consolidation. Further information is available at medpace.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy